Selective Antitumor Effect and Lower Toxicity of Mitochondrion-Targeting Derivatization of Triptolide

Area of Science:

• Pharmacology
• Biochemistry
• Oncology

Background:

• Triptolide exhibits potent antitumor activity but is limited by significant toxicity.
• Mitochondrion-targeting strategies offer potential for selective cancer therapy due to higher mitochondrial membrane potential (MMP) in tumor cells.

Purpose of the Study:

• To develop novel triptolide derivatives using mitochondrion-targeting carriers to enhance selective antitumor effects and reduce toxicity.
• To evaluate the efficacy and safety of these derivatives in lung cancer models.

Main Methods:

• Structural modification of triptolide using lipophilic cations triphenylphosphonium and F16.
• In vitro evaluation of antitumor activity, mitochondrial accumulation, apoptosis induction, reactive oxygen species generation, and MMP changes in cancer cells (NCI-H1975) and normal cells (BEAS-2B).
• In vivo toxicity assessment in zebrafish.

Main Results:

• F16-bearing triptolide derivatives retained antitumor activity, overcame inhibition plateau, and improved selectivity in lung cancer.
• The derivative F9 effectively accumulated in cancer cell mitochondria, induced apoptosis, increased reactive oxygen species, and reduced MMP.
• F9 demonstrated significantly lower developmental, renal, and liver toxicities in zebrafish compared to triptolide, with no observed effects on normal cells.

Conclusions:

• Mitochondrion-targeting modification of triptolide is a promising strategy to overcome its toxicity limitations.
• The derivative F9 shows enhanced selective antitumor efficacy and improved safety profile, offering a potential therapeutic candidate for lung cancer.